Devgen's mission is to deliver the next green revolution in rice to growers that cultivate 60m ha rice in India and S.E. Asia.
Devgen uses advanced biotechnology and molecular breeding technology to develop the Next Generation Hybrid Rice (NGHR) and crop protection solutions with a superior environmental profile:
- Devgen developed the next generation of hybrid rice, improving yield, seed productivity, grain quality, and tolerance to biotic and abiotic stress factors. Devgen strongly believes that this hybrid rice technology has the potential to drive the accelerated conversion of varietal rice to hybrid rice.
- Anticipating the need to increase insect resistance and drought/heat tolerance in rice to a level that is beyond what can be achieved with classical breeding, Devgen created a portfolio of biotech traits using own technology as well as in-licensed technologies.
- Devgen established an integrated seed business in India and Southeast Asia through which its rice crops and technologies reach the market.
- In India, Devgen complemented its hybrid rice business with geographically and seasonally complementary crops: hybrid sorghum, pearl millet and sunflower.
- In its Crop Protection unit, Devgen develops a novel nematicide, an agro-chemical product that protects crops from damage by parasitic nematodes. This product is sold in Turkey and in the US.
- Devgen innovates in crop protection research and environment induced stress tolerance for its own crops and providing technology to corporate partners.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), and has subsidiaries in Singapore, Hyderabad (India), Yogyakarta (Indonesia), General Santos (Philippines) and Delaware (US), totaling about 280 employees.
Key in enabling these discoveries is the company’s ability to model these complex human diseases involving multiple organs and complex physiological processes in the model organism C. elegans in combination with the company’s associated RNAi knockdown technology. Metabolic diseases and their complications (diabetes, obesity and arrhythmia) are an important and growing disease area representing significant unmet medical needs in which the pharmaceutical industry seeks to strengthen its preclinical and clinical pipelines, paying premium prices due to the scarcity of novel concepts and programs.
Devgen believes that it should be in a position to out-license some of its programs in this area to potential partners within the next 12 to 24 months. In the event an out-licensing agreement is effectively put in place, this could provide a substantial upside for the company.
More on Devgen Human Therapeutics |
|
| Breaking news
Interim Report 2011
Annual Report 2010
Annual Brochure 2010
|
|